CATALYST:
Enhancing Clinical Decision-Making and Optimizing Health Outcomes in Hematologic Malignancies—Focus on CLL and AML

FACULTY

Michael R. Grunwald, MD
Chief, Leukemia Division
Associate Professor
Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute, Atrium Health
Charlotte, NC

Ryan Jacobs, MD
Principle Investigator of CLL Clinical Trials
Department of Hematology, Lymphoma Division
Assistant Professor of Medicine
Levine Cancer Institute, Atrium Health
Charlotte, NC

LEARNING OBJECTIVES

• Summarize the relevance of molecular markers and genetic data relevant to selection of therapy in CLL or AML
• Review relevant treatment best practices in both newly diagnosed and relapsed/refractory AML in consideration of disease- and patient-specific factors to inform shared decision-making
• Evaluate potential adverse events associated CLL and AML therapies to implement appropriate monitoring and counseling

TARGET AUDIENCE

This enduring activity is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with CLL and/or AML.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with CLL and/or AML.

CNE Credits: 2.0 ANCC Contact Hours

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 2.0 contact hours of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Michael R. Grunwald, MD discloses the following: Consulting fee: AbbVie, Amgen, Astellas Pharma, Bristol Myers Squibb, Cardinal Health, CTI Biopharma, Daiichi Sankyo, Gilead Sciences, Incyte Corporation, Invitae Corporation, Karius, Novartis, Ono Pharmaceutical, Pfizer, Pharmacosmos, Premier, Servier Pharmaceuticals, Sierra Oncology, and Stemline Therapeutics. Contracted research for Janssen and Incyte.

Ryan Jacobs, MD discloses the following: Consulting fee: Adaptive, BeiGene, Genentech, Janssen, MorphoSys, SecuraBio, TG Therapeurics, and Pharmcyclis. Speaker Bureau for Abbvie, AstraZeneca, BeiGene, Janssen, Pharmacyclics, SecuraBio, and Pharmcyclis. Contracted Research for: LOXO Oncology, MEI Pharma, Pharmacyclics, TeneoBio, TG Therapeutics and Pharmcyclis.

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff, Planners and Managers

The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:

• Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
• Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
• Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
• Angela Davis, PhD, Medical Director of Med Learning Group, has nothing to disclose.
• Michael R. Page, PharmD, Medical Director of Med Learning Group, discloses an ownership stake in Advantific, LLC.
• Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
• Melissa A. Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
• Amanda Jenkins, Program Manager for Med Learning Group has nothing to disclose.
• Natalie Smith, Program Coordinator for Med Learning Group has nothing to disclose.
• Daniel DaSilva, Outcomes and Accreditation Coordinator for Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:

1. Read the CME/CNE information and faculty disclosures.
2. Participate in the enduring activity.
3. Complete and submit the evaluation form to Med Learning Group.

You will receive your certificate after the enduring activity.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected]

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

RELEASED DATE: November 4, 2022
EXPIRATION DATE: November 4, 2023

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.